tetano
Editor, Senior Moderator
Arch Soc Esp Oftalmol (Engl Ed)
. 2021 Jul;96(7):347-352.
doi: 10.1016/j.oftale.2020.12.007. Epub 2021 May 19.
Impact of novel coronavirus infection in patients with uveitis associated with an autoimmune disease: Result of the COVID-19-GEAS patient survey
P Fanlo[SUP] 1 [/SUP], G Espinosa[SUP] 2 [/SUP], A Adán[SUP] 3 [/SUP], R Arnáez[SUP] 4 [/SUP], A Fonollosa[SUP] 5 [/SUP], H Heras[SUP] 6 [/SUP], J Oteiza[SUP] 4 [/SUP], B Del Carmelo Gracia Tello[SUP] 7 [/SUP], L Sáez Comet[SUP] 8 [/SUP], L Pallarés[SUP] 9 [/SUP]
Affiliations
Abstract
Introduction: The objective of these study is to know the characteristics of COVID-19 in patients with uveitis associated with Systemic Autoimmune Disease (SAD) through telematic survey.
Material and methods: Internal Medicine Society and Group of Systemic Autoimmune disease conducted a telematic survey of patients with SAD to learn about the characteristics of COVID-19 in this population.
Results: A total of 2,789 patients answered the survey, of which 28 had a diagnosis of uveitis associated with SAE. The majority (82%) were female and caucasian (82%), with a mean age of 48 years. The most frequent SAEs were Behçet's disease followed by sarcoidosis and systemic lupus erythematosus. 46% of the patients were receiving corticosteroid treatment at a mean prednisone dose of 11 mg/day. Regarding infection, 14 (50%) patients reported symptoms compatible with SARS-CoV-2 infection. RT-PCR was performed on the nasopharyngeal smear in two patients and in one of them (4%) it was positive.
Conclusions: Both asymptomatic and symptomatic COVID-19 patients with ASD-associated UNI had received similar immunosuppressive treatment.
Keywords: Anti-TNF-alpha therapy; COVID-19; Corticoides; Corticosteroids; Immunosuppression; Inmunosupresión; Tratamiento anti-TNF alfa; Uveitis; Uveítis.
. 2021 Jul;96(7):347-352.
doi: 10.1016/j.oftale.2020.12.007. Epub 2021 May 19.
Impact of novel coronavirus infection in patients with uveitis associated with an autoimmune disease: Result of the COVID-19-GEAS patient survey
P Fanlo[SUP] 1 [/SUP], G Espinosa[SUP] 2 [/SUP], A Adán[SUP] 3 [/SUP], R Arnáez[SUP] 4 [/SUP], A Fonollosa[SUP] 5 [/SUP], H Heras[SUP] 6 [/SUP], J Oteiza[SUP] 4 [/SUP], B Del Carmelo Gracia Tello[SUP] 7 [/SUP], L Sáez Comet[SUP] 8 [/SUP], L Pallarés[SUP] 9 [/SUP]
Affiliations
- PMID: 34217471
- DOI: 10.1016/j.oftale.2020.12.007
Abstract
Introduction: The objective of these study is to know the characteristics of COVID-19 in patients with uveitis associated with Systemic Autoimmune Disease (SAD) through telematic survey.
Material and methods: Internal Medicine Society and Group of Systemic Autoimmune disease conducted a telematic survey of patients with SAD to learn about the characteristics of COVID-19 in this population.
Results: A total of 2,789 patients answered the survey, of which 28 had a diagnosis of uveitis associated with SAE. The majority (82%) were female and caucasian (82%), with a mean age of 48 years. The most frequent SAEs were Behçet's disease followed by sarcoidosis and systemic lupus erythematosus. 46% of the patients were receiving corticosteroid treatment at a mean prednisone dose of 11 mg/day. Regarding infection, 14 (50%) patients reported symptoms compatible with SARS-CoV-2 infection. RT-PCR was performed on the nasopharyngeal smear in two patients and in one of them (4%) it was positive.
Conclusions: Both asymptomatic and symptomatic COVID-19 patients with ASD-associated UNI had received similar immunosuppressive treatment.
Keywords: Anti-TNF-alpha therapy; COVID-19; Corticoides; Corticosteroids; Immunosuppression; Inmunosupresión; Tratamiento anti-TNF alfa; Uveitis; Uveítis.